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Rivastigmine for HIV-associated
neurocognitive disorders
A randomized crossover pilot study
Objective: To assess the efficacy and safety of rivastigmine for the treatment of HIV-associated
neurocognitive disorders (HAND) in a cohort of long-lasting aviremic HIV1 patients.
Methods: Seventeen aviremic HIV1 patients with HAND were enrolled in a randomized, double-blind,
placebo-controlled, crossover study to receive either oral rivastigmine (up to 12mg/day for 20 weeks)
followed by placebo (20weeks) or placebo followed by rivastigmine. Efficacy endpoints were improve-
ment on rivastigmine in the Alzheimer’s Disease Assessment Scale–Cognitive subscale (ADAS-Cog)
and individual neuropsychological scores of information processing speed, attention/working memory,
executive functioning, and motor skills. Measures of safety included frequency and nature of adverse
events and abnormalities on laboratory tests and on plasma concentrations of antiretroviral drugs.
Analyses of variance with repeated measures were computed to look for treatment effects.
Results: There was no change on the primary outcome ADAS-Cog on drug. For secondary outcomes,
processing speed improved on rivastigmine (Trail Making Test A: F1,13 5 5.57, p 5 0.03). One mea-
sure of executive functioning just failed to reach significance (CANTAB Spatial Working Memory
[strategy]: F1,13 5 3.94, p 5 0.069). No other change was observed. Adverse events were frequent,
but not different from those observed in other populations treated with rivastigmine. No safety issues
were recorded.
Conclusions: Rivastigmine in aviremic HIV1 patients with HAND seemed to improve psychomotor
speed. A larger trial with the better tolerated transdermal form of rivastigmine is warranted.
Classification of evidence: This study provides Class III evidence that rivastigmine is ineffective for
improving ADAS-Cog scores, but is effective in improving some secondary outcomemeasures in avire-
mic HIV1 patients with HAND.
GLOSSARY
AD 5 Alzheimer disease; ADAS-Cog 5 Alzheimer’s Disease Assessment Scale–Cognitive subscale; CANTAB 5 Cambridge
Neuropsychological Test Automated Battery; cART 5 combined antiretroviral therapy; ChEI 5 cholinesterase inhibitors;
DSM-IV 5 Diagnostic and Statistical Manual of Mental Disorders, 4th edition; HAD 5 HIV-associated dementia; HAD-
A 5 Hospital Anxiety and Depression scale–anxiety; HAD-D 5 Hospital Anxiety and Depression scale–depression;
HAND 5 HIV-associated neurocognitive disorders; HDS 5 HIV Dementia Scale; LP 5 lumbar puncture; MND 5 mild neuro-
cognitive disorders;MOS-HIV 5Medical Outcome Study HIV Health Survey; NNRTI 5 non-nucleoside reverse transcriptase
inhibitors; PD 5 Parkinson disease; QoL 5 quality of life; SWM 5 Spatial Working Memory; TDM 5 therapeutic drug mon-
itoring; TMT 5 Trail Making Test.
HIV-associated neurocognitive disorders (HAND) remain common in the era of combined
antiretroviral therapy (cART),1–3 even in the context of long-lasting viral load suppression.4
For this reason, the study of adjunctive cognitive enhancers to treat HIV1 patients with HAND
appears of major importance. To date, the efficacy of cholinesterase inhibitors (ChEI) has never
been investigated.
A putative favorable effect of ChEI in patients with HAND has been hypothesized based on sim-
ilarities existing between HAND and Alzheimer disease (AD). Indeed, there is evidence for increased
amyloid deposition in the brains of patients with AIDS at autopsy,5,6 even in cART-treated patients,7
and for reduced levels of amyloid-b 1-42 in the CSF of patients with HAND.8,9 Additionally,
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amyloid-b precursor protein was detected in the
brains of asymptomatic HIV1 patients, demon-
strating an early deposit of this neurotoxic
protein.10
The status of the cholinergic system has not
been examined in patients with HAND. How-
ever, in a cellular model of HIV-associated
dementia (HAD), the adjunction of galant-
amine, a ChEI, resulted in the inhibition of
microglial activation induced by HIV-1 protein
gp120.11 Interestingly, choline acetyltransferase,
a major enzyme in the synthesis of acetylcholine,
is also markedly diminished in the putamen and
hippocampus of simian immunodeficiency
virus–infected monkeys early in the course of
infection.12 Based on the above data, we con-
ducted a randomized, double-blind, placebo-
controlled, crossover pilot study to assess the
efficacy and safety of rivastigmine, a ChEI, to
treat HAND in a cohort of long-lasting aviremic
HIV1 patients.
METHODS Study subject recruitment. From March 2009
to April 2010, recruitment of participants was performed within
the Swiss HIV Cohort Study at the HIV outpatients clinics of
both Lausanne and Geneva University Hospitals, and in affiliated
private practices.
Inclusion criteria were 1) undetectable HIV-1 RNA concentra-
tions in both plasma (,20 copies/mL for.3 months before study
entry) and CSF (,200 copies/mL) and 2) diagnosis of HAND
(mild neurocognitive disorders [MND] or HAD) according to
the Frascati criteria.13 Patients with asymptomatic neurocognitive
impairment were not considered for the study. Exclusion criteria
were 1) history of major CNS opportunistic infection affecting the
brain, 2) any other opportunistic infection not affecting the brain
,12 months before study entry, 3) active recreational drug use,
4) major depression according to DSM-IV criteria or any other
known psychiatric condition possibly interfering with the safe con-
duct of the study, 5) brain MRI showing mass effect or signs indi-
cating an ongoing tumor or abscess, and 6) use of cholinergic or
anticholinergic agents within 2 weeks prior to screening. Patients
with incidental comorbid conditions (e.g., history of remote drug
abuse, hepatitis C coinfection) were not excluded.
Standard protocol approvals, patient consents, and
organization. The trial was held in both the Lausanne (designated
as coordinating center) and the Geneva University Hospitals. It was
approved by the internal review boards of both university hospitals
and by the Swiss Agency for Therapeutic Products (SWISSMED-
IC, no. 2008DR3368). Rivastigmine was purchased fromNovartis.
The CHUV pharmacy department was in charge of preparing iden-
tical placebos, packaging all capsules, and distributing study drugs
to both sites. HIV1 patients who met the inclusion criteria for
participation in the trial received written information about the
study procedure and possible side effects of rivastigmine, and signed
written informed consent.
Safety phone calls were planned once a week to ensure adher-
ence to treatment (estimation of the number of forgotten doses)
and record adverse events. Patients with mild side effects were
instructed by phone on how to reduce drug doses. Those with
more severe adverse events were scheduled for an intermediate
medical visit at study site. Every 2 weeks, drug escalation was
reminded during the phone call. At the end of each study arm,
the remaining capsules were computed (adherence check).
Patients were not asked to guess whether they were taking riva-
stigmine or placebo. They were informed that the investigators
were blinded to treatment arms and that randomization would
be known at the end of the study.
The study was conducted in accordance with the guidelines
for Good Clinical Practice and the Declaration of Helsinki.
Study design. This was a randomized, double-blind, placebo-
controlled, crossover study. The primary research question
assessed by Class III evidence was to evaluate whether rivastig-
mine was safe and could improve global cognition as measured
by the Alzheimer’s Disease Assessment Scale–Cognitive subscale
(ADAS-Cog)14 in aviremic HIV1 patients with HAND. Second-
ary research questions assessed by Class III evidence concerned
efficacy on specific cognitive domains and quality of life (QoL).
At the screening visit, patients underwent a complete neurobeha-
vioral examination to assess the presence of HAND (detailed hereaf-
ter). Patients fulfilling the diagnostic criteria for MND or HAD and
agreeing to participate in the study were planned for a second visit
within 7 days to complete the following assessments: 1) physical
and neurologic examination, 2) brain MRI to exclude acute ongoing
pathologies and guarantee that lumbar puncture (LP) could be per-
formed safely, 3) serial blood testing consisting of complete blood
count, coagulation function tests, electrolytes (Na, K, glucose), renal
(urea, creatinine) and liver function tests (transaminases, alkaline
phosphatase, and bilirubin), 4) measurement of the plasmatic activity
of acetylcholinesterase to monitor adherence to treatment, using the
QuantiChromTM Acetylcholinesterase Assay Kit (BioAssay Systems,
Hayward, CA) according to manufacturer’s instructions, 5) routine
therapeutic drug monitoring (TDM) of measurable cART (non-
nucleoside reverse transcriptase inhibitors [NNRTI], protease inhib-
itors, and integrase inhibitors) to subsequently verify the absence of
significant interaction with rivastigmine, and 6) LP to ensure unde-
tectable viral load in the CSF. Patients who fulfilled all the criteria
were randomized and started the study immediately.
During the first arm (20 weeks), the drug dosage started at
1.5 mg/day and was progressively increased every 2 weeks
(3 mg, 4.5 mg, 6 mg, 9 mg, and 12 mg/day). The procedure
was identical for rivastigmine and placebo. At the end of first
arm, the complete set of assessments previously described was per-
formed again. A washout period of 6 weeks was then observed to
avoid any carryover effect of the drug such as it was demonstrated
in a similar designed study conducted in Parkinson disease (PD)
dementia.15 The procedure during the second arm was similar
and was preceded by a third neurobehavioral examination. At the
end of the second arm, the complete set of assessments was
performed for the last time.
Neurobehavioral examination. Neuropsychological testing.
HIV1 participants underwent the ADAS-Cog,14 originally devel-
oped to assess cognitive dysfunction in patients with AD and
systematically used in clinical trials assessing ChEI, and a neuro-
psychological evaluation of cognitive domains known to be
impaired in patients with HAND: 1) information processing
speed (Reaction Time [RTI] from the Cambridge Neuropsycho-
logical Test Automated Battery [CANTAB],16 Trail Making Test
part A [TMT-A],17 Wechsler Adult Intelligence Scale–III Symbol
Digit test)18; 2) attention/working memory (CANTAB Rapid
Visual Information Processing and Spatial Working Memory
[SWM, error component],16 digit spans backward/forward)18;
3) executive functioning (TMT part B [TMT-B],17 CANTAB
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SWM [strategy component], and Stockings of Cambridge)16; and
4) motor skills (RTI [motor component]).16 For all the tests used,
a z score was calculated based on available normative data. Finally,
the HIV Dementia Scale (HDS)19 and International HDS20 were
performed.
Psychiatric questionnaires. Trained psychologists (S.S.,
A.R.A., M.M.) conducted an interview at baseline using a French
questionnaire assessing the presence of mood disorders according
to the DSM-IV diagnostic criteria (Questionnaire de Santé du
Patient) to rule out major depression. Current mood was then
assessed at each visit using the Hospital Anxiety and Depression
scale21 addressing depressive (HAD-D) and anxious (HAD-A)
symptoms, separately. Patients were considered to express
depressed or anxious signs if the HAD-D or HAD-A subscale
score was $10/21.
Functional assessment. The impact of cognitive difficulties on
everyday functioning (e.g., housework, social life, employment) was
evaluated at each visit through the subjective complaints reported
by HIV1 patients.4 In addition, we administered the Medical
Outcome Study HIV Health Survey (MOS-HIV),22 a question-
naire assessing health-related QoL.
Outcome measures. The primary endpoint for efficacy was de-
signed as an improvement from baseline to week 20 (on drug) in
the ADAS-Cog score. Other individual neuropsychological scores
were secondary endpoints. Additional efficacy measures included
change in self-reported QoL (MOS-HIV). Concerning safety, end-
points were the frequency and nature of adverse events, abnormalities
on laboratory tests, and TDM of antiretroviral drugs.
Statistical methods. Power calculation was based on the results of
previous clinical trials using rivastigmine in patients with AD and pa-
tients with PD. The study was initially designed to provide a$80%
power to detect a $2.8-point difference between rivastigmine and
placebo on the ADAS-Cog, and a$0.3–0.5 point difference on the
CANTAB tests, requiring a sample size of 24 patients.
Statistical analyses were conducted using a Stata 11 software pack-
age. Differences at baseline between patients enrolled in arm 1 (riva-
stigmine followed by placebo) vs arm 2 (placebo followed by
rivastigmine) on demographic and clinical variables, mood symptoms,
behavioral, and QoL scores were examined using x2 tests for the
comparison of categorical variables, and t tests or Mann-Whitney
rank sum tests (depending on the distribution) for the comparison
of continuous variables. Significance was set at p , 0.05 for all
statistics. Results are expressed in mean 6 SD, except for Mann-
Whitney rank sum tests, expressed in median 6 interquartile
intervals.
To estimate the efficacy of rivastigmine, the difference between
the score obtained for a single measure at the beginning and at the
end of each 20-week study period was computed (visit 2 2 visit
1 and visit 4 2 visit 3) for each participant, and the difference
between these 2 values was used as a combined outcome for each
subject. On this outcome, analysis of variance with repeated meas-
ures, with treatment (rivastigmine vs placebo) as a within effect and
sequence of treatment (arm 1 vs arm 2) as a between factor, were
performed. Each outcome was considered as a single dependent
variable and, since only one statistical analysis was performed per
outcome, corrections for multiple comparisons were not applied.
Patients with one or more missing values in a study period were
excluded from efficacy analyses of that period.
RESULTS Baseline characteristics. From the 50 HIV1
patients screened, 17 (12 men/5 women, age 55.1 6
9.7 years, years of education 12.6 6 2.8) fulfilled
inclusion criteria and agreed to participate in this clin-
ical trial (figure 1). Their mean disease duration since
diagnosis and mean time with undetectable HIV vire-
mia were 14.26 7.1 and 5.16 3.5 years, respectively.
The mean CD4 count was 668.9 6 222.2 cells/mm3
and the mean CD4 nadir was 176.6 6 100.7 cells/
mm3. All participants were on stable antiretroviral reg-
imen for a mean time of 2.16 1.6 years. Four patients
changed their cART during the course of the study
because of tolerability issues (interactions with use of
proton pump inhibitors in one, dyslipidemia in the
second, nightmares in the third, altered renal function
consecutive to nephrectomia in the fourth patient).
Changes were not related to rivastigmine, as reflected
by the fact that 3 patients were on placebo at the time
of treatment change. They increased the CNS pene-
trating-effectiveness score by 1 point in 2 patients (1
on placebo and 1 on drug). At enrollment, all patients
were found to have mild to moderate cognitive impair-
ment with decreased everyday functioning, thus
Figure 1 Study design and flow diagram of trial participation
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fulfilling diagnostic criteria for MND. No patient was
diagnosed with HAD.
Nine patients were randomized to arm 1 and 8 to
arm 2. Treatment arms were comparable with respect
to demographics and clinical characteristics except for
duration of aviremia and duration of cART (table 1).
Baseline cognitive scores were equal in both treatment
arms (table 2). One patient enrolled in arm 2 had to be
excluded during the study because of reported active
drug use. Final analysis was performed on 12 patients
remaining on treatment until study termination and 3
patients withdrawing because of side effects when
already taking high doses of treatment (9–12 mg/day)
and thus close to study end. Adherence measured dur-
ing phone calls and by capsules counts was satisfactory
(#2 missed tablets per week). Acetylcholinesterase
activity measured in the plasma decreased in 9 patients
(reduction rate 41.7 6 19.5%), thus indicating good
compliance, whereas levels did not change in 6 patients.
Efficacy analyses. Changes on rivastigmine and placebo
for each efficacy measure are reported in table 3. There
was no improvement on drug on the primary outcome
ADAS-Cog (figure 2A). Concerning secondary out-
comes, one measure of processing speed improved
due to treatment effect (TMT A) (figure 2B). There
was no other improvement on drug but one measure of
executive functioning just failed to reach significance
(CANTAB SMW [strategy component]).
Safety analyses. Rivastigmine induced mild to mod-
erate adverse events in 9 patients (nausea/vomiting,
unsteadiness). In these cases, the attitude was to reduce
the dosage to the previous level (causing no side effects).
Five patients could not sustain the maximal dose of 12
mg/day of rivastigmine and performed the study at an
inferior dosage (9 mg/day). Four patients withdrew
because of persistent nausea (n5 1), nightmares/anxiety
(n 5 1), and cutaneous rashes (n 5 2). Among the
patients who did not drop out, the mean dose of riva-
stigmine at study end was 10.3 6 2.7 mg/day.
Blood analyses did not reveal severe abnormalities
on rivastigmine. However, slightly increased levels of
glucose (n 5 7; mean level after rivastigmine: 7.2 6
1.3 mmol/L [normal range 3.7–5.6 mmol/L]) and
transaminases (ALAT) (n 5 3; mean level after riva-
stigmine: 64.56 4.5 U/L [normal range 9–36 U/L]),
and decreased levels of hemoglobin (n 5 3; mean
level after rivastigmine: 120.7 6 5.1 g/L [normal
range 133–177 g/L]), were observed in some patients
after 20 weeks of rivastigmine.
TDM did not show any significant negative impact
of rivastigmine on plasma concentrations of antiretrovi-
ral agents. A downward trend of antiretroviral levels in 4
patients taking NNRTI (2 patients on efavirenz, 1 on
nevirapine, and 1 on etravirine) and 1 patient receiving
a raltegravir-based regimen was observed. HIV RNA lev-
els did not change during exposure to rivastigmine (,20
copies in all patients throughout the study).
DISCUSSION This pilot study suggests that a treat-
ment of rivastigmine for 20 weeks improves psycho-
motor speed and, marginally, executive functioning
Table 1 Baseline demographics and clinical characteristics
Treatment arm 1
(rivastigmine–placebo) (n 5 9)
Treatment arm 2
(placebo–rivastigmine) (n 5 8) p Valuea
Age, y, mean (SD) 54.71 (9.52) 54.58 (10.33) 0.979
Education, y, mean (SD) 12.22 (3.31) 12.63 (2.33) 0.778
Male, n (%) 5 (44) 7 (88) 0.294
HIV diagnosis, y, mean (SD) 15.73 (6.83) 11.82 (7.11) 0.267
Duration of aviremia, y, mean (SD) 7.02 (3.25) 2.97 (2.10) 0.009b
CD4 count, mean (SD) 660.89 (265.94) 659.0 (167.33) 0.987
Nadir CD4 count, mean (SD) 141.22 (90.21) 209.38 (100.21) 0.161
Duration of cART treatment, y, median (IQR) 14.7 (2.24) 12.02 (8.41) 0.027b,c
CPE score, mean (SD) 8.11 (2.52) 7.0 (0.76) 0.251
HDS score, mean (SD) 8.94 (4.34) 9.94 (3.28) 0.606
International HDS score, mean (SD) 8.83 (2.54) 8.56 (1.40) 0.792
HAD-A score, mean (SD) 9.11 (5.01) 10.50 (3.51) 0.523
HAD-D score, mean (SD) 6.56 (5.41) 7.0 (4.31) 0.855
Abbreviations: cART 5 combined antiretroviral therapy; CPE 5 CNS penetrating-effectiveness; HAD-A 5 Hospital Anxiety
and Depression scale–anxiety; HAD-D 5 Hospital Anxiety and Depression scale–depression; HDS 5 HIV Dementia Scale;
IQR 5 interquartile range.
aStatistics are t tests, except where noted.
bSignificant.
cMann-Whitney rank sum test.
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in HIV1 patients with HAND and undetectable
HIV viral load in both plasma and CSF. No signifi-
cant change was detected in the primary and other
secondary endpoints. Our cohort was small and the
above results need to be confirmed in a larger trial,
but these findings appear encouraging.
Indeed, several cognitive enhancers and neuroprotec-
tive agents with different modes of action (antioxi-
dants,23–25 antiapoptotic drugs,26,27 calcium channel
blockers,28 CCR5 antagonists,29 platelets activating fac-
tors antagonists,30 tumor necrosis factor antagonists,31 N-
methyl-D-aspartate antagonist,32,33 and minocycline34)
have already been studied in patients with HAND with-
out convincing results. As a matter of fact, none of these
compounds is currently recommended in practice. Riva-
stigmine may represent a treatment alternative in avire-
mic patients with HAND.
Rivastigmine was preferred to the other ChEI
drugs currently in use, donepezil and galantamine,
because of a lower risk of interactions with cART.
Indeed, rivastigmine is not metabolized by cyto-
chrome P450 (CYP450) and, most importantly, does
not affect it. TDM ensured that rivastigmine had
globally no significant negative influence on plasma
concentrations of cART. The possible downward
trend observed on NNRTI levels would need further
analyses on a larger cohort to be confirmed. In fact,
the small cohort, the variety of cART used, and the
fact that some patients changed their regimen during
the study precluded precise statistics.
Blood analyses did not reveal severe safety issues
during the study. Side effects (mostly nausea) were
frequent (76%) but did not differ in nature from
Table 2 Baseline neuropsychological results (standardized z scores)a
Treatment arm 1
(rivastigmine–placebo)
(n 5 9)
Treatment arm 2
(placebo–rivastigmine)
(n 5 8) p Value
ADAS-Cog 20.50 (1.30) 21.53 (1.19) 0.113
RTI reaction time 20.63 (1.16) 23.31 (4.77) 0.122
RTI movement time 0.16 (1.39) 20.34 (1.51) 0.488
RVIP 21.34 (1.16) 21.97 (0.79) 0.216
SWM errors 21.22 (0.88) 20.73 (0.72) 0.237
SWM strategy 21.15 (0.59) 20.51 (1.28) 0.201
Trail Making Test A 22.02 (2.26) 22.49 (2.44) 0.682
Trail Making Test B 23.16 (4.10) 22.21 (1.91) 0.561
SOC correct problems 21.07 (0.77) 20.41 (1.15) 0.202
Symbol Digit test 21.00 (1.23) 21.08 (0.71) 0.868
Digit span backward 21.22 (1.34) 21.95 (1.65) 0.334
Digit span forward 20.44 (1.25) 21.24 (0.96) 0.165
Abbreviations: ADAS-Cog 5 Alzheimer’s Disease Assessment Scale–Cognitive subscale; RTI 5 reaction time; RVIP 5 rapid
visual information processing; SOC 5 Stockings of Cambridge; SWM 5 Spatial Working Memory.
aValues are mean z scores (SD). Statistics are t tests.
Table 3 Analysis of variance with repeated measures computed for each
efficacy variable on a combined outcome ([rivastigmine visit 22 visit 1]
2 [placebo visit 2 2 visit 1]), using treatment (rivastigmine vs placebo)
as a within effect and sequence of treatment (arm 1 vs arm 2) as a
between factora
Mean combined
outcome (SD) Fb p Value
ADAS-Cog 20.09 (1.14) F1,13 5 0.31 0.589
RTI reaction time 20.53 (2.94) F1,13 5 1.87 0.195
RTI movement time 0.68 (2.62) F1,13 5 0.45 0.512
RVIP 20.12 (1.26) F1,13 5 0.03 0.858
SWM errors 0.19 (1.24) F1,13 5 0.08 0.786
SWM strategy 0.44 (0.88) F1,13 5 3.94 0.068
Trail Making Test A 1.20 (1.89) F1,13 5 5.57 0.034c
Trail Making Test B 0.22 (3.28) F1,13 5 0.06 0.816
SOC correct problems 0.26 (0.95) F1,12 5 1.17 0.301
Symbol Digit test 0.11 (0.66) F1,13 5 0.27 0.613
Digit span backward 0.08 (2.17) F1,13 5 0.00 0.946
Digit span forward 20.03 (2.21) F1,13 5 0.03 0.867
MOS-HIV perceived healthd 0.20 (21.18) F1,13 5 0.06 0.804
MOS-HIV social functiond 29.53 (56.09) F1,13 5 0.70 0.418
MOS-HIV cognitive functiond 16.87 (34.76) F1,13 5 2.71 0.124
MOS-HIV mental healthd 4.67 (31.24) F1,13 5 0.12 0.730
MOS-HIV global quality of lifed 14.73 (43.58) F1,13 5 1.45 0.249
Abbreviations: ADAS-Cog 5 Alzheimer’s Disease Assessment Scale–Cognitive subscale;
MOS-HIV 5 Medical Outcome Study HIV Health Survey; RTI 5 reaction time; RVIP 5 rapid
visual information processing; SOC 5 Stockings of Cambridge; SWM 5 Spatial Working
Memory.
a Values are z scores, except where noted.
b Treatment main effect.
c Significant.
dRaw scores.
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those known to occur in patients with AD taking
ChEI.35 The dropout rate (23%) also remained com-
parable to those reported in clinical trials with
patients with AD.36 Tolerability issues might be
solved in future studies by the use of a transdermal
form of rivastigmine, currently available for the treat-
ment of patients with AD. Rivastigmine patches pro-
vide the advantage of a continuous delivery of drug
over 24 hours and were demonstrated to offer a
greater tolerability than oral rivastigmine.36 In
addition, the patch provides a higher dosage (20
cm2 patch, delivering 17.4 mg/24 hours), which of-
fers better cognitive benefits with similar
tolerability.36
There are several methodologic limitations to the
interpretation of our results. The first one is the small
size of our cohort and the attrition rate that certainly
reduced the power of the study. Another issue is that
some patients did not reach the target dosage of 12
mg/day of rivastigmine. Even lower doses of ChEI
were reported to be effective in studies conducted with
patients with AD35 but in a small pilot study, this might
have reduced the observable effects. Adherence was cer-
tainly good in at least 60% of study subjects, as indicated
by a marked reduction of the plasmatic acetylcholines-
terase activity. The plasmatic enzymatic activity was
unchanged in the remaining 40%. Although other meas-
ures of adherence (phone calls, capsules counts) sug-
gested that the observance was satisfactory, we cannot
rule out that, in these 6 subjects (40%), the adherence
was suboptimal, possibly in relation with adverse events,
such as nausea. For the same reason, it is likely that
blinding of the study was not perfect and that some
patients guessed when they were on rivastigmine. Finally,
the duration of the study was short, while clinical trials
with patients with AD are generally conducted over a
longer period than 24 weeks.35
Despite the above-mentioned issues, this pilot
study is to our knowledge the first one assessing the
efficacy and safety of a ChEI to treat HAND. It
was conducted in a population of cART-treated pa-
tients with long-lasting undetectable plasma HIV
viral load, undetectable CSF viral load, and no major
psychiatric or other comorbidity interfering with cog-
nition, thus patients who were already optimally trea-
ted, and yet had HAND.
This pilot study emphasizes that rivastigmine in
aviremic HIV1 patients with HAND could be effec-
tive to improve cognitive functions typically affected
by HIV, such as information processing speed. There
are several safety issues, in particular nausea, which
may preclude usefulness of oral rivastigmine. How-
ever, a transdermal form of rivastigmine is now avail-
able. A larger trial with this better tolerated form is
warranted to confirm our findings.
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